Tags: drug pricing, Germany, Section 301, USTR, market access, reimbursement

US launches probe of German 'underpayment' for medicines

By FieldPulse Editorial · June 23, 2026

A new US Section 301 probe into German medicine pricing raises trade, reimbursement, and access questions that could ripple into broader pharma pricing strategy.

The US government has opened a Section 301 investigation into German drug pricing and reimbursement policy, escalating a long-running pricing argument into a trade dispute with possible downstream effects for global pharma strategy.

According to pharmaphorum, the probe targets what US officials describe as persistent underpayment for innovative medicines under Germany's pricing framework and raises the possibility of punitive trade action.

This matters because Germany is not a minor pricing market.

Its reimbursement approach carries influence far beyond one country, especially when international reference pricing and cross-market comparisons shape how manufacturers think about launch sequencing, access expectations, and long-term pricing strategy.

If Washington uses trade pressure to push Germany toward higher pricing or different reimbursement terms, companies may try to use that shift in broader conversations elsewhere.

Pharmaphorum reported that the investigation comes despite last year's US-EU trade deal, which said pharma tariffs would not exceed 15%.

It also lands while Germany is advancing broad reforms to its reimbursement and rebate policies in an effort to reduce healthcare spending.

Those reforms have already prompted resistance from the pharma industry.

The article said Pfizer, Eli Lilly, Boehringer Ingelheim, and AstraZeneca have all warned that Germany's current direction could affect capital investment and even decisions about when or whether to launch new medicines there.

That makes this more than abstract geopolitics.

It is tied to the commercial conditions under which innovative medicines are launched, priced, and defended.

Pharmaphorum also noted that Germany and other European countries are facing pressure to change how they assess the cost-effectiveness of innovative medicines after the UK recently revised its framework under a US trade agreement.

In other words, this is part of a wider political push on international drug-pricing structures, no.